Immunome (IMNM) Q3 2026 earnings review
Immunome's lymphoma drug shrinks tumors, while trial costs jump
Immunome, a clinical-stage cancer drug developer, showed its first lymphoma drug shrinks tumors even as operating expenses climb. In early Phase 1 data, chief executive Clay B. Siegall reported that IM-1021 shrank tumors in 53% of evaluable B-cell lymphoma patients, while European regulators accepted the approval filing for its lead tumor pill, varegacestat. Meanwhile, operating costs grew 50% from a year ago to $90 million as the company started new clinical trials.
| IM-1021 lymphoma response rate | 53% 64% in DLBCL subtype (19 evaluable patients) |
|---|---|
| Total operating expenses | $90.4M +50% from a year ago |
| Cash and marketable securities | $461.6M down $58.4M from last quarter by our math |
| Cash runway outlook | Unchanged funds operations into 2028 |
⚖️ Verdict: 🟢 Bullish
The story got better because the early lymphoma responses provide the first human proof that the company's proprietary chemotherapy payload works. In addition, clearing IM-1340 for human trials puts a fourth drug on track for the clinic by year-end. One caution: 52% of lymphoma patients on IM-1021 had serious side effects, mainly low white blood cell counts, and overhead costs nearly doubled ahead of next year's planned drug launch.
The question now is whether IM-1021's tumor responses hold up across more patients without forcing doctors to cut doses for safety. Either the white blood cell drops are manageable with standard care, or they restrict how much drug patients can tolerate. The updated Phase 1 presentation at the hematology conference on December 14 will provide the answer.
🐂 Bull Case
IM-1021 Shrinks Tumors in Over Half of Lymphoma Patients
Immunome is testing IM-1021, an antibody-drug conjugate (ADC, a targeted therapy that delivers chemotherapy directly to cancer cells) aimed at the ROR1 protein. In initial Phase 1 data from a June cutoff, the drug shrank tumors in 53% of evaluable patients with B-cell non-Hodgkin lymphoma, a blood cancer. That included 10 of 19 patients, with five seeing their cancer disappear completely.
Results were stronger in diffuse large B-cell lymphoma, an aggressive subtype, where 64% of patients (7 of 11) responded and three had complete responses. Because the drug produced responses across all tested dose levels, the early data validates the company's proprietary HC74 payload, the cancer-killing chemical attached to the antibody.
What to watch: the updated Phase 1 presentation at the American Society of Hematology meeting on December 14, 2026. A similar response rate across a larger group of patients, along with data on how long the responses last, would support moving the drug into larger trials.
Varegacestat Clears Regulatory Milestones in the US and Europe
Varegacestat is an oral gamma secretase inhibitor, a pill designed to block cell signals that drive tumor growth, developed "for the treatment of adults with desmoid tumors". Chief executive Clay B. Siegall said: "We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA."
The European Medicines Agency validated the Marketing Authorization Application (MAA, the European approval filing) in October, beating the company's prior target of a submission by year-end. Because both US and European regulators are now reviewing the drug following Phase 3 trials that cut disease progression risk by 84%, the developer is on track for its first commercial launch next year.
What to watch: the US Food and Drug Administration action date on April 28, 2027. Approval on that date would shift the biotech from a pure research organization into a commercial drug seller.
Clinical Pipeline Expands Toward Four Active Trials
The drugmaker is using its HC74 payload to build a line of therapies for solid tumors. "Beyond varegacestat, we now have three programs in the clinic, with IM-1340 expected to become the fourth by year-end," Siegall said. In June and July, doctors dosed the first patients with IM-1617, a solid tumor ADC, and IM-3050, a radioligand therapy that delivers targeted radiation to tumors.
In September, the FDA cleared the Investigational New Drug application (IND, the authorization required to begin human trials) for IM-1340, "a potential first-in-class ADC directed at an undisclosed solid tumor target". Because three separate drugs using the HC74 chemical payload are moving into human testing, the company has multiple chances to prove its technology works outside blood cancers.
What to watch: the start of the IM-1340 Phase 1 trial and the IND submission for another candidate, IM-1335, both planned before the end of 2026. Hitting both targets would confirm the research team can sustain its pace of new trial launches.
🐻 Bear Case
Half of IM-1021 Patients Had Serious Side Effects
Siegall said: "We made significant progress across our oncology pipeline in recent months." While IM-1021 shrank tumors in its first human study, the treatment also caused frequent side effects among the 25 B-cell lymphoma patients treated by the June cutoff.
- Any treatment-emergent adverse event (side effect during the trial): 92% of patients
- Grade 3 or higher adverse events (serious side effects): 52% of patients
- Serious neutropenia (a drop in white blood cells that fight infection): 44% of patients
Nearly half of the patients experienced serious neutropenia, which is a common side effect of chemotherapy payloads. If higher doses cause too many blood cell drops, doctors may have to cap the dose or delay treatments, which could limit how well the drug works over time.
What to watch: the safety breakdown by dose level at the December 14 hematology meeting. High rates of treatment discontinuations or dose reductions would narrow the drug's path forward.
Pre-Launch Hiring and Trial Expansion Drive Up Costs
Running three clinical trials while preparing to sell varegacestat is making the business much more expensive to operate. Total operating expenses rose 50.3% from a year ago to $90.4 million, widening the third-quarter net loss to $85.8 million. Even excluding non-cash stock-based compensation of $12.8 million, operating costs grew 45.3% to $77.6 million by our math.
Research and development spending rose 41.3% to $69.5 million, while general and administrative costs (management, legal and commercial preparation overhead) jumped 90.6% to $20.9 million. Because the company will soon add a fourth clinical trial and build a sales force for varegacestat, quarterly spending is set to stay high before any product revenue arrives.
What to watch: fourth-quarter general and administrative expenses in the annual report. Another step up ahead of the April 2027 FDA decision would mean faster cash usage next year.
👓 Other Themes
Cash Balance Supports Operations Into 2028
Immunome ended September with $461.6 million in unrestricted cash and marketable securities, down $58.4 million from the second quarter by our math because rising accrued liabilities delayed some cash payments. At the third-quarter pace of cash reduction, the balance covers 7.9 quarters by our math, matching the company's plan "to fund operations into 2028" past the varegacestat approval decision.
💲 Other KPIs
Weighted-average shares rose 29.1% from a year ago because the oncology company sold stock in a $460.5 million public offering in December 2025. Compared with the second quarter, the share count grew 0.3%, so the higher share count kept net loss per share growth to 16.9% despite a 49.3% wider net loss.
Accrued expenses (bills owed for clinical trials and operations not yet paid in cash) rose 22.8% from last quarter to $36.5 million. Long-term operating lease liabilities more than doubled from June to $10.3 million, which helped conserve cash during the third quarter.
Interest earned on cash and marketable securities rose 70.8% from a year ago because of the cash raised in December 2025. However, interest income fell from $5.5 million in the first quarter and $5.0 million in the second quarter as the drug developer spent down its cash balance.
🔮 Guidance
Unchanged. Immunome still expects its $461.6 million in cash and marketable securities to fund operations into 2028. That is the fourth straight quarter the company has maintained this timeline since raising capital in December 2025. By our math, the five quarters from September 2026 to the start of 2028 allow up to $92 million of quarterly cash spending.
❓ Key Questions
How did IM-1021 side effects vary across dose levels?
Grade 3 or higher side effects occurred in 52% of lymphoma patients, led by neutropenia at 44%. Knowing whether blood cell drops cluster at the highest doses will show if doctors can use a safer dose without losing tumor responses.
How long do IM-1021 tumor responses last?
The initial cutoff showed a 64% response rate in diffuse large B-cell lymphoma across 11 patients, with three complete responses. Durability data at the December meeting will determine if the drug can compete in a crowded lymphoma treatment market.
What are the molecular targets for IM-1617, IM-1340 and IM-1335?
Immunome is advancing three solid tumor antibody-drug conjugates using its HC74 payload, but keeps all three biological targets secret. Naming the targets will let investors evaluate the patient pool and rival drugs in development.
How much will the varegacestat commercial buildout cost in 2027?
General and administrative expenses nearly doubled from a year ago to $20.9 million in the third quarter. With the April 2027 FDA decision approaching, the size of the planned sales team will govern next year's cash burn.